Mendel Money Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.38M | Sell |
10,942
-217
| -2% | -$48.1K | 1% | 35 |
|
|
2025
Q4 | $2.55M | Sell |
11,159
-220
| -2% | -$50.1K | 1.07% | 30 |
|
|
2025
Q3 | $2.63M | Sell |
11,379
-529
| -4% | -$108K | 1.11% | 29 |
|
|
2025
Q2 | $2.21M | Buy |
11,908
+161
| +1% | +$29.9K | 0.98% | 36 |
|
|
2025
Q1 | $2.46M | Sell |
11,747
-528
| -4% | -$103K | 1.17% | 28 |
|
|
2024
Q4 | $2.18M | Buy |
12,275
+760
| +7% | +$140K | 0.97% | 35 |
|
|
2024
Q3 | $2.27M | Sell |
11,515
-1,552
| -12% | -$290K | 0.98% | 32 |
|
|
2024
Q2 | $2.24M | Sell |
13,067
-216
| -2% | -$35.8K | 1.05% | 33 |
|
|
2024
Q1 | $2.42M | Sell |
13,283
-396
| -3% | -$68.2K | 1.12% | 33 |
|
|
2023
Q4 | $2.12M | Buy |
13,679
+4,467
| +48% | +$651K | 1.02% | 33 |
|
|
2023
Q3 | $1.37M | Buy |
9,212
+470
| +5% | +$69K | 0.74% | 40 |
|
|
2023
Q2 | $1.18M | Buy |
8,742
+854
| +11% | +$125K | 0.61% | 44 |
|
|
2023
Q1 | $1.26M | Sell |
7,888
-7,141
| -48% | -$1.09M | 0.68% | 40 |
|
|
2022
Q4 | $2.43M | Buy |
15,029
+350
| +2% | +$53.7K | 1.38% | 28 |
|
|
2022
Q3 | $1.97M | Buy |
14,679
+685
| +5% | +$98.3K | 1.23% | 29 |
|
|
2022
Q2 | $2.14M | Sell |
13,994
-655
| -4% | -$100K | 1.28% | 28 |
|
|
2022
Q1 | $2.38M | Buy |
14,649
+4,364
| +42% | +$634K | 1.16% | 32 |
|
|
2021
Q4 | $1.39M | Sell |
10,285
-410
| -4% | -$48.4K | 0.8% | 30 |
|
|
2021
Q3 | $1.15M | Sell |
10,695
-45
| -0.4% | -$5.14K | 0.72% | 32 |
|
|
2021
Q2 | $1.21M | Sell |
10,740
-550
| -5% | -$61.9K | 0.76% | 34 |
|
|
2021
Q1 | $1.22M | Sell |
11,290
-100
| -0.9% | -$10.7K | 0.8% | 32 |
|
|
2020
Q4 | $1.22M | Buy |
11,390
+320
| +3% | +$30.8K | 0.85% | 29 |
|
|
2020
Q3 | $970K | Buy |
11,070
+120
| +1% | +$11.3K | 0.76% | 31 |
|
|
2020
Q2 | $1.07M | Buy |
+10,950
| New | +$964K | 0.95% | 28 |
|
|
2019
Q4 | $922K | Sell |
10,412
-180
| -2% | -$14.9K | 0.8% | 29 |
|
|
2019
Q3 | $802K | Buy |
10,592
+200
| +2% | +$13.7K | 0.74% | 30 |
|
|
2019
Q2 | $756K | Buy |
+10,392
| New | +$817K | 0.72% | 30 |
|
|
2018
Q3 | $947K | Buy |
+10,017
| New | +$950K | 0.92% | 29 |
|
|
2017
Q4 | $1.04M | Buy |
+10,751
| New | +$1.01M | 1% | 29 |
|
|
2015
Q2 | $746K | Hold |
11,103
| – | – | 0.69% | 35 |
|
|
2015
Q1 | $650K | Hold |
11,103
| – | – | 0.6% | 34 |
|
|
2014
Q4 | $727K | Sell |
11,103
-300
| -3% | -$18.9K | 0.68% | 35 |
|
|
2014
Q3 | $659K | Buy |
+11,403
| New | +$633K | 0.64% | 36 |
|
Other funds holding ABBV
VCM
VPM
Mendel Money Management's ABBV Position: Q1 2026 in Review
Mendel Money Management reduced its AbbVie (ABBV) stake by 1.9% in Q1 2026, selling an estimated $48.1K and leaving 10,942 shares worth $2.38M. The position accounts for 1% of the portfolio, ranked #35.
Mendel Money Management first reported a position in ABBV in Q3 2014 and has held it in 33 quarters since. The position peaked at $2.63M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Mendel Money Management held 10,942 shares of AbbVie worth $2.38M as of Q1 2026.
- Mendel Money Management sold 217 AbbVie shares in Q1 2026, an estimated $48.1K.
- AbbVie made up 1% of Mendel Money Management's portfolio in Q1 2026, its #35 holding.
- Mendel Money Management first reported a position in AbbVie in Q3 2014 and has held it in 33 quarters since.
- Mendel Money Management's AbbVie position peaked at $2.63M in Q3 2025.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Mendel Money Management's 13F filing for Q1 2026, filed 4 May 2026.